The global biosimulation market attained a value of USD 3.50 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 16.90%, to reach USD 16.68 Billion by 2034.
Base Year
Historical Period
Forecast Period
Recent data predicts that cancer incidence is expected to rise, reaching 35 million new cases by 2050. Biosimulation stands as a promising strategy to accelerate oncology drug development to meet the growing clinical needs of cancer patients.
In March 2023, Certara, Inc., launched Simcyp Simulator Version 22, a physiologically based pharmacokinetics (PBPK) platform with updated features and novel capabilities for drug development processes.
Technological advancement and upgradation in biosimulation software including integration of machine learning and artificial intelligence (AI) are projected to augment market demand in the forecast period.
Compound Annual Growth Rate
16.9%
Value in USD Billion
2025-2034
*this image is indicative*
Biosimulation, a relatively new tool in healthcare and pharmaceutical drug development, allows researchers to simulate complex biological systems. It helps to predict drug behavior, reduces costs and time as compared to conventional experiments, and optimizes treatment strategies. These factors are likely to augment biosimulation market growth in coming years.
The rising adoption of biosimulation software by key market players can be attributed to its ability to predict clinical outcomes before the occurrence of human clinical trials. This approach not only expedites drug development timelines but also minimizes risks associated with failed trials. Such factors fuel the rising market demand. Moreover, the rise in healthcare expenditure and technological advancements in the field are also expected to fuel the market share.
Advancements in computational power, growing focus on chronic diseases, increasing demand for personalized medicine, and expansion in biosimulation applications comprise some of the key trends and developments in the market.
Certara acquired Applied Biomath, an innovative biotechnology company to industrialize quantitative systems pharmacology (QSP) biosimulation methods. Utilizing the expertise of Applied Biomath, the company intends to expand biosimulation capabilities including predicting the optimal dosing regimen for novel therapies.
Simulations Plus Inc. acquired Immunetrics Inc. (a odelling and simulation company specializing in oncology, immunology, and autoimmune diseases) at a deal worth USD 15.5 million in cash along with USD 1.8 million hold-back, and USD 8 million depending on revenue performance. The acquisition will reinforce the existing quantitative systems pharmacology (QSP) software and service capabilities at Simulations Plus, increasing the therapeutic areas covered via QSP models by 50%.
Certara, Inc.The leading biosimulation company launched Simcyp Simulator Version 22, a physiologically based pharmacokinetics (PBPK) platform with updated features and novel capabilities for drug development processes. The company Simcyp Simulator has proven its utilization across 300 label claims for 90+ novel drugs, replacing the need for human clinical trials.
Cellworks announced the launch of two new business units, leveraging biosimulation for novel precision oncology drug testing to accelerate drug development timelines and reduce costs. Utilizing its biosimulation and computational model (CBM), the personalized therapy biosimulation company aims to predict patient response, streamline clinical trials, and aid in biomarker development, among others, potentially transforming the drug development process.
As more and more pharmaceutical companies are recognising the significance of biosimulation software in expediting drug development processes, the market is witnessing major investments to integrate and improve simulation systems. The simulation models are increasingly employed to test drugs in a virtual environment before conducting expensive and time-consuming clinical trials, which is bolstering the biosimulation market value.
The market is also driven by the rising strategic partnerships between the leading market players, novel product launches, and the growing complexity of drug development fuelling the demand for biosimulation tools and services.
"Global Biosimulation Market Report and Forecast 2025-2034" offers a detailed analysis of the market based on the following segments:
Breakup by Product and Services
Breakup by Delivery Model
Breakup by Application
Breakup by End User
The key market players are contributing to the biosimulation market growth through strategic mergers and acquisitions initiatives, novel product launches, and continuous R&D efforts aimed at technological advancement.
| Company | Year Founded | Headquarters | Products/Services |
| Certara Inc. | 2008 | Princeton, New Jersey, USA | Specializes in biosimulation software and consulting services for drug development such as pharmacokinetic/pharmacodynamic (PK/PD) modelling |
| Dassault Systemes | 1981 | Vélizy-Villacoublay, France | Offers a broad range of software applications for simulation, 3D design, and digital manufacturing, including BIOVIA modelling and simulation software. |
| Simulation Plus | 1996 | Lancaster, California, USA | Provides modelling and simulation software for pharmaceutical research and development, focusing on absorption, distribution, metabolism, excretion, and toxicity modelling |
| Schrodinger Inc. | 1990 | New York, USA | Provides software solutions and services for drug discovery, including a computational platform offering predictive modelling to assist molecular discovery |
Other key players in the market include Advanced Chemistry Development Inc., Physiomics PLC, Genedata AG, Thermo Fisher Scientific, Immunetrics, BioSimulation Consulting Inc., Yokogawa Insillico Biotechnology GmbH, and Chemical Computing Group ULC, among others.
North America is the leading regional market, owing to the presence of key players and advanced healthcare system which is witnessing rapid digitization. The higher adoption rates of in-silico models in drug development and discovery processes is also driving market growth. Moreover, the rising prevalence of chronic diseases in the region is expected to fuel the biosimulation market size in the forecast period.
Asia Pacific is projected to experience exponential growth which can be attributed to the rising research and development activities in the region. Further, the increased impetus of the government to improve healthcare infrastructure and patient outcomes is likely to boost the market size.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 3.50 Billion in 2024 driven by the technological innovations in biosimulation software across the globe.
The market is anticipated to grow at a CAGR of 16.90% during the forecast period of 2025-2034, likely to reach a market value of USD 16.68 Billion by 2034.
Growing preference for personalized medicine along with increasing investments in research and development sector are fuelling the market demand.
One of the significant trends in the market is the increased acquisition and merger initiatives by the key market players. In December 2023, Certara acquired Applied Biomath, an innovative biotechnology company, to industrialize quantitative systems pharmacology (QSP) biosimulation methods.
Based on the products and services, the market is segmented into software comprising molecular modeling and simulation software, PBPK modeling and simulation software, trial design software, toxicity prediction software, and other biosimulation software. Services include in-house services and contract services.
Based on the delivery model, the market includes a subscription model and an ownership model.
Major end users of the market include pharmaceutical and biotechnology companies, contract research organizations, academic research institutes, and others.
Applications of the market include drug discovery and drug development. Drug discovery includes pre-clinical testing and clinical trials, and drug development encompasses target identification, validation, lead identification, and optimization, among others.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
Key players involved in the market are Certara Inc., Dassault Systemes, Simulation Plus, Schrodinger Inc., Advanced Chemistry Development Inc., Physiomics PLC, Genedata AG, Thermo Fisher Scientific, Immunetrics, BioSimulation Consulting Inc., Yokogawa Insillico Biotechnology GmbH, and Chemical Computing Group ULC.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product and Services |
|
| Breakup by Delivery Model |
|
| Breakup by Application |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share